Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Filings indexed 1,323 across all filing types
Latest filing 2024-01-05 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-01-05 English
Regulatory Filings 2024
Regulatory Filings
2024-01-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company will present at the J.P. Morgan Healthcare Conference and has issued a press release and slide presentation related to this event. The document includes a Regulation FD Disclosure and references exhibits such as a press release and presentation slides. There are no financial statements or detailed financial data included, only announcements about upcoming presentations and related materials. The document length is 3884 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP) update announced via Form 8-K, but since the actual presentation is attached as an exhibit and the 8-K is primarily an announcement of the presentation, the most appropriate classification is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories, especially since the 8-K is a general current report and not a full report or earnings release.
2024-01-05 English
Regulatory Filings 2024
Regulatory Filings
2024-01-03 English
FORM 4
Director's Dealing
2024-01-02 English
Regulatory Filings 2023
Regulatory Filings
2023-12-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.